Scholar Rock's Apitegromab Phase 3 Success: Path to 2025 …

Oct 7, 2024 · Scholar Rock announced positive Phase 3 trial results for its SMA drug candidate, apitegromab, planning to file for U.S. and EU approval in Q1 2025.

CouponFollow Extension

$345
OFF

Scholar Rock's SMA Drug Hits Phase 3 Trial Goals; Secures $345M …

3 weeks from now

Nov 12, 2024 · Scholar Rock achieves significant milestone in SMA treatment with positive Phase 3 results, strengthens financial position with $345M offering, extending runway through 2026.

stocktitan.net

$2
OFF

Scholar Rock Preps Filings After SMA Antibody Clears Trial

3 weeks from now

Oct 8, 2024 · Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug apitegromab clears a phase 3 trial, with filings now expected in Q1 2025.

pharmaphorum.com

$300
OFF

Scholar Rock Scores $300M For Regulatory Filings & Launch Plans …

3 weeks from now

Oct 9, 2024 · The stock sale follows the company’s Phase 3 data readout earlier this week showing its drug, apitegromab, met the goal of showing muscle function improvement in spinal …

medcitynews.com

320%
OFF

Scholar Rock Shares Soar 320% On Positive SMA Trial Results

3 weeks from now

Jan 24, 2025 · Shares of Scholar Rock Holdings surged an astonishing 320% on Monday, a remarkable leap fueled by the announcement of promising results from its Phase 3 SAPPHIRE …

thefinancialanalyst.net

300%
OFF

Scholar Rock’s Shares Soar 300% After Phase III Win In ... - BioSpace

3 weeks from now

Oct 8, 2024 · Scholar Rock on Monday announced that its investigational myostatin blocker apitegromab aced the Phase III SAPPHIRE trial in spinal muscular atrophy, demonstrating …

biospace.com

335%
OFF

Scholar Rock (SRRK.US) Stock Surges 335% As Its SMA Candidate …

3 weeks from now

Oct 8, 2024 · Scholar Rock Holding Corp. (SRRK.US) saw its stock price soar 335% during Monday's trading, driven by the successful achievement of the primary endpoint in the third …

ainvest.com

320%
OFF

Scholar Rock (SRRK) Shares Soar Over 320% On SMA Topline …

3 weeks from now

New York, October 07, 2024 - PRISM MarketView - The late-stage biopharmaceutical company Scholar Rock (SRRK) who focuses on treatments for spinal muscular atrophy (SMA), …

prismmarketview.com

FAQs about Scholar Rock's Apitegromab Phase 3 Success: Path to 2025 … Coupon?

Will scholar rock get regulatory approval after positive SMA results?

Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate. ...

Is scholar rock pursuing a Phase 3 trial in spinal muscular atrophy?

An experimental, muscle-preserving therapy from Scholar Rock succeeded in a Phase 3 trial in spinal muscular atrophy, positioning the biotechnology company to seek approvals in the U.S. and Europe early next year. ...

How much did Scholar Rock Raise in a stock offering?

On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. ...

Why did Scholar Rock's stock increase 362% After Phase III data?

Scholar Rock’s stock price increased by 362% after the company announced its Phase III data. Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot ...

Does scholar rock have an anti-myostatin inhibitor apitegromab?

Scholar Rock has done well to advance its anti-myostatin inhibitor apitegromab for the treatment of patients with Spinal Muscular Atrophy [SMA]. Especially, when you consider that it was able to submit its BLA of this drug to the FDA for review. ...

How long does it take for SMA to work?

This trial enrolled 188 SMA patients ages 2 to 21. In preliminary results reported Monday, Scholar Rock said the drug achieved statistically significant and clinically meaningful improvement at 12 months, measured according to a scale used to assess muscle function in SMA patients (a higher score indicates better muscle function). ...